Skip to main content
Figure 2 | BMC Immunology

Figure 2

From: Tissue transglutaminase treatment leads to concentration-dependent changes in dendritic cell phenotype - implications for the role of transglutaminase in coeliac disease

Figure 2

Endocytic characteristics of DCs following treatment with ECM proteins. Endocytic ability of the DCs, at 48 h, was assessed by the uptake of FITC-dextran using flow cytometry (n = 2). Data were gated, based on forward/side scatter characteristics and on FITC channel to exclude dead cells and contaminating clumps of FITC-dextran. Error bars represent standard deviations. * p < 0.05. NB: Statistical analysis is based on differences between means of untreated control (CTRL) and treated samples. Sample treatments correspond to untreated (CTRL), 0.01% FN, 1% BSA and TG-2 activity defined as 0.039 U/mL (TG-2 [high]), 0.0036 U/mL (TG-2 [mid]) or 0.00022 U/mL (TG-2 [low]).

Back to article page